We respect the good faith of the parties in this debate and are not questioning their credibility. However, the topic is of great interest and not to be ignored. The bald facts are WHO queries the benefits of four COVID drugs in terms of patient experiences. These medications are, in order: Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon-β1a.
Basis on Which WHO Queries the Benefits of Four COVID Drugs
First the WHO studied records of 11,266 randomized patients in 405 hospitals in 30 countries. Then they divided these into groups each using one of the four subject COVID drugs, plus patients taking a combination of Lopinavir and Ritonavir. A third of the study group (the control) did not receive any of these medications.
WHO’s objective was to compare the mortality rates of users of those treatments with the control group. We append a link to the full World Health Organization report at the end of this post. But again, we emphasize our intention is to summarize the WHO’s findings, as opposed to debating the merits.
The World Health Organization’s Results and Conclusions
WHO queries the benefits of four COVID drugs because ‘these Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19 patients. It makes this claim based on ‘overall mortality, start of ventilation, and duration of hospital stays’.
We believe health authorities need to get to the bottom of these WHO findings. That’s because they fly in the face of previous opinions by respected authorities. We have no doubt this debate will continue with strong opinions from both sides. Once again, we are not questioning the good faith of the parties to this debate. But we believe this is a time to stand together.
Related
Remdesivir: Clear Cut Power to Fight the Coronavirus?
Interferon Beta Offers Fresh Hope in Pandemic
Preview Image: Impression of the Corona Virus
